Table 1.
Clinical characteristics of discovery and validation cohorts.
| Characteristics | PD-L1 | PFS | ||
|---|---|---|---|---|
| CHUM (Discovery) |
IUCPQ (Validation) |
CHUM (Discovery) |
IUCPQ (Validation) |
|
| Gender, n (%) | ||||
| Female | 97 (50.5) | 69 (51.4) | 78 (52.3) | 51(46.8) |
| Male | 95 (49.4) | 65 (48.5) | 71 (47.6) | 58(53.2) |
| Age (mean) | 66.6 ± 8.9 | 67.8 ± 6.9 | 66.2 ± 8.73 | 67.9 ± 7.38 |
| Smoking status, n (%) | ||||
| Former | 126 (66.7) | 89 (66.4) | 93 (63.4) | 75 (68.8) |
| Current | 55 (29.1) | 37 (27.6) | 43 (29.5) | 27 (24.8) |
| Never | 8 (4.2) | 8 (6.0) | 10 (7.1) | 7 (6.4) |
| ECOG status, n (%) | ||||
| 0 | 67 (34.9) | 36 (64.1) | 53 (35.6) | 29 (26.5) |
| 1 | 93 (48.4) | 82 (28.0) | 69 (46.3) | 66 (60.5) |
| 2 | 28 (14.6) | 7 (5.5) | 23 (15.4) | 6 (5.5) |
| 3 | 4 (2.1) | 3 (2.4) | 4 (2.7) | 2 (2.0) |
| NA 6 (5.5) | ||||
| PD-L1 expression, n (%) | ||||
| < 50% | 95(50.1) | 81 (60.5) | ||
| > 50% | 97 (49.9) | 53 (39.5) | – | – |
| PFS, n, (%) | ||||
| Short-term | 74 (50) | 54 (50) | ||
| Long-term | – | – | 75 (50) | 55 (50) |